A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

NCT00002183 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Abacavir sulfate
DRUG: Amprenavir
DRUG: Lamivudine
DRUG: Zidovudine

Sponsor

Glaxo Wellcome